Four insights:
1. Royal Biologics develops biologics, orthobiologics and orthopedic implants used in stem cells and other surgical procedures.
2. This is the first healthcare investment of Granite Creek’s recently closed $200 million FlexCap II fund.
3. The investment will be used to expedite new hires, expand operations, increase product development and pursue acquisitions.
4. Two partners at Granite Creek — Jim Clark and Mark Radzik — will serve on the board of Royal Biologics.
More articles on biologics:
Ortho RTi unveils new CEO — 4 quick insights
Minnesota seeks to expand stem cell research through state initiative — 4 insights
Stem cell controversies — Where we are in 2019
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
